Cytos Biotechnology Aktie
WKN: A2ALS5
ISIN: CH0325814116
Land: Schweiz
Branche: Chemie, Pharma, Bio- & Medizintechnik
Sektor: Biotechnologie
Gratis: Die zehn beliebtesten Rüstungs-Aktien im Check! Info...
29,10 EUR -0,15 EUR -0,51 %
19:22:02 L&S RT
Komplette Navigation anzeigen

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Freitag, 08.03.24 07:00
Monitoransicht mit Chart.
Bildquelle: pixabay

Kuros Biosciences AG / Key word(s): Annual Results
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

08.03.2024 / 07:00 CET/CEST

-    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST

Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.  Following the announcement, the company will host a video conference call at 3pm CET/10am US EST to discuss the results. 

To register for the video call, click here. 

For further information, please contact:

Kuros Biosciences AG 
Daniel Geiger
Chief Financial Officer
t: +41 44 733 47 47
e: [email protected]		 LifeSci Advisors 
Sandya von der Weid
Investors
t: +41 78 680 0538
e: [email protected]

About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across three continents and in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit kurosbio.com.


End of Media Release
Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: [email protected]
Internet: www.kurosbio.com
ISIN: CH0325814116
Valor: 32581411
Listed: SIX Swiss Exchange
EQS News ID: 1854131

 
End of News EQS News Service

1854131  08.03.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1854131&application_name=news&site_id=boerse_de



Quelle: DGAP



myChampions100PLUS Einzelkontenverwaltung ab 500.000 Euro